PTC Therapeutics, Inc.
PTCT
$71.70
-$0.27-0.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 360.52M | 272.55M | 164.68M | 211.01M | 178.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 360.52M | 272.55M | 164.68M | 211.01M | 178.88M |
| Cost of Revenue | 119.07M | 129.70M | 140.08M | 115.94M | 124.41M |
| Gross Profit | 241.45M | 142.85M | 24.60M | 95.07M | 54.47M |
| SG&A Expenses | 80.63M | 86.18M | 96.87M | 84.05M | 85.26M |
| Depreciation & Amortization | 11.84M | 11.58M | 9.35M | 7.53M | 4.06M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 211.54M | 227.47M | 246.30M | 207.52M | 213.73M |
| Operating Income | 148.98M | 45.09M | -81.62M | 3.49M | -34.86M |
| Income Before Tax | 97.55M | -2.46M | -139.08M | -23.07M | -71.05M |
| Income Tax Expenses | 14.05M | 347.00K | -4.12M | -38.97M | -6.20M |
| Earnings from Continuing Operations | 83.50M | -2.81M | -134.97M | 15.90M | -64.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.50M | -2.81M | -134.97M | 15.90M | -64.85M |
| EBIT | 148.98M | 45.09M | -81.62M | 3.49M | -34.86M |
| EBITDA | 164.85M | 60.50M | -68.72M | 14.60M | -27.28M |
| EPS Basic | 1.01 | -0.03 | -1.67 | 0.20 | -0.83 |
| Normalized Basic EPS | 0.76 | -0.03 | -1.16 | -0.25 | -0.57 |
| EPS Diluted | 0.92 | -0.03 | -1.67 | 0.20 | -0.83 |
| Normalized Diluted EPS | 0.69 | -0.03 | -1.16 | -0.23 | -0.57 |
| Average Basic Shares Outstanding | 83.01M | 82.52M | 80.69M | 78.47M | 78.15M |
| Average Diluted Shares Outstanding | 92.02M | 82.52M | 80.69M | 87.12M | 78.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |